Cargando…
Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma
BACKGROUND & AIMS: The metabolic dysfunction-associated fatty liver disease (MAFLD) is a new inclusive term proposed to replace non-alcoholic fatty liver disease (NAFLD). We analysed whether hepatocellular carcinoma (HCC) risk differs by MAFLD or NAFLD status in a large sample of asymptomatic ad...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10393797/ https://www.ncbi.nlm.nih.gov/pubmed/37538246 http://dx.doi.org/10.1016/j.jhepr.2023.100810 |
_version_ | 1785083222720249856 |
---|---|
author | Song, Byeong Geun Choi, Sung Chul Goh, Myung Ji Kang, Wonseok Sinn, Dong Hyun Gwak, Geum-Youn Paik, Yong-Han Choi, Moon Seok Lee, Joon Hyeok Paik, Seung Woon |
author_facet | Song, Byeong Geun Choi, Sung Chul Goh, Myung Ji Kang, Wonseok Sinn, Dong Hyun Gwak, Geum-Youn Paik, Yong-Han Choi, Moon Seok Lee, Joon Hyeok Paik, Seung Woon |
author_sort | Song, Byeong Geun |
collection | PubMed |
description | BACKGROUND & AIMS: The metabolic dysfunction-associated fatty liver disease (MAFLD) is a new inclusive term proposed to replace non-alcoholic fatty liver disease (NAFLD). We analysed whether hepatocellular carcinoma (HCC) risk differs by MAFLD or NAFLD status in a large sample of asymptomatic adults. METHODS: A cohort comprising 73,691 adults were followed up for the development of HCC. NAFLD was diagnosed among participants without other liver diseases (n = 65,992). RESULTS: Participants with MAFLD showed higher incidence of HCC than those without MAFLD (0.37 and 0.24 per 1,000 person-years, respectively; p = 0.006). However, MAFLD was not an independent factor associated with HCC in multivariable adjusted analysis (hazard ratio [HR] 1.21; 95% CI 0.92–1.60). When stratified according to presence of other liver diseases, MAFLD was not associated with HCC in participants with other liver diseases. In participants without other liver diseases, both MAFLD (adjusted HR 1.84; 95% CI 1.09–3.11) and NAFLD (adjusted HR 1.71; 95% CI 1.01–2.90) were independent factors associated with HCC. When stratified according to NAFLD and MAFLD status, there was no HCC development among participants with NAFLD only during 8,936 person-years of follow-up, but this NAFLD-only group comprised 3.4%, and the majority of participants with hepatic steatosis fulfilled both NAFLD and MAFLD criteria. CONCLUSIONS: In patients with other chronic liver diseases, the presence of MAFLD is not independently associated with an increased risk of HCC. For those without other chronic liver diseases, MAFLD largely overlaps with NAFLD and is associated with an increased risk of HCC. IMPACT AND IMPLICATIONS: This study investigated the usefulness of newly proposed nomenclature, metabolic dysfunction-associated fatty liver disease (MAFLD), over non-alcoholic fatty liver disease (NAFLD), in terms of predicting hepatocellular carcinoma. In patients with other chronic liver diseases, the presence of MAFLD is not independently associated with an increased risk of HCC. However, for those without chronic liver disease, MAFLD largely overlaps with NAFLD and is associated with an increased risk of HCC. |
format | Online Article Text |
id | pubmed-10393797 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-103937972023-08-03 Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma Song, Byeong Geun Choi, Sung Chul Goh, Myung Ji Kang, Wonseok Sinn, Dong Hyun Gwak, Geum-Youn Paik, Yong-Han Choi, Moon Seok Lee, Joon Hyeok Paik, Seung Woon JHEP Rep Research Article BACKGROUND & AIMS: The metabolic dysfunction-associated fatty liver disease (MAFLD) is a new inclusive term proposed to replace non-alcoholic fatty liver disease (NAFLD). We analysed whether hepatocellular carcinoma (HCC) risk differs by MAFLD or NAFLD status in a large sample of asymptomatic adults. METHODS: A cohort comprising 73,691 adults were followed up for the development of HCC. NAFLD was diagnosed among participants without other liver diseases (n = 65,992). RESULTS: Participants with MAFLD showed higher incidence of HCC than those without MAFLD (0.37 and 0.24 per 1,000 person-years, respectively; p = 0.006). However, MAFLD was not an independent factor associated with HCC in multivariable adjusted analysis (hazard ratio [HR] 1.21; 95% CI 0.92–1.60). When stratified according to presence of other liver diseases, MAFLD was not associated with HCC in participants with other liver diseases. In participants without other liver diseases, both MAFLD (adjusted HR 1.84; 95% CI 1.09–3.11) and NAFLD (adjusted HR 1.71; 95% CI 1.01–2.90) were independent factors associated with HCC. When stratified according to NAFLD and MAFLD status, there was no HCC development among participants with NAFLD only during 8,936 person-years of follow-up, but this NAFLD-only group comprised 3.4%, and the majority of participants with hepatic steatosis fulfilled both NAFLD and MAFLD criteria. CONCLUSIONS: In patients with other chronic liver diseases, the presence of MAFLD is not independently associated with an increased risk of HCC. For those without other chronic liver diseases, MAFLD largely overlaps with NAFLD and is associated with an increased risk of HCC. IMPACT AND IMPLICATIONS: This study investigated the usefulness of newly proposed nomenclature, metabolic dysfunction-associated fatty liver disease (MAFLD), over non-alcoholic fatty liver disease (NAFLD), in terms of predicting hepatocellular carcinoma. In patients with other chronic liver diseases, the presence of MAFLD is not independently associated with an increased risk of HCC. However, for those without chronic liver disease, MAFLD largely overlaps with NAFLD and is associated with an increased risk of HCC. Elsevier 2023-06-28 /pmc/articles/PMC10393797/ /pubmed/37538246 http://dx.doi.org/10.1016/j.jhepr.2023.100810 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Research Article Song, Byeong Geun Choi, Sung Chul Goh, Myung Ji Kang, Wonseok Sinn, Dong Hyun Gwak, Geum-Youn Paik, Yong-Han Choi, Moon Seok Lee, Joon Hyeok Paik, Seung Woon Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma |
title | Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma |
title_full | Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma |
title_fullStr | Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma |
title_full_unstemmed | Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma |
title_short | Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma |
title_sort | metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10393797/ https://www.ncbi.nlm.nih.gov/pubmed/37538246 http://dx.doi.org/10.1016/j.jhepr.2023.100810 |
work_keys_str_mv | AT songbyeonggeun metabolicdysfunctionassociatedfattyliverdiseaseandtheriskofhepatocellularcarcinoma AT choisungchul metabolicdysfunctionassociatedfattyliverdiseaseandtheriskofhepatocellularcarcinoma AT gohmyungji metabolicdysfunctionassociatedfattyliverdiseaseandtheriskofhepatocellularcarcinoma AT kangwonseok metabolicdysfunctionassociatedfattyliverdiseaseandtheriskofhepatocellularcarcinoma AT sinndonghyun metabolicdysfunctionassociatedfattyliverdiseaseandtheriskofhepatocellularcarcinoma AT gwakgeumyoun metabolicdysfunctionassociatedfattyliverdiseaseandtheriskofhepatocellularcarcinoma AT paikyonghan metabolicdysfunctionassociatedfattyliverdiseaseandtheriskofhepatocellularcarcinoma AT choimoonseok metabolicdysfunctionassociatedfattyliverdiseaseandtheriskofhepatocellularcarcinoma AT leejoonhyeok metabolicdysfunctionassociatedfattyliverdiseaseandtheriskofhepatocellularcarcinoma AT paikseungwoon metabolicdysfunctionassociatedfattyliverdiseaseandtheriskofhepatocellularcarcinoma |